プレゼンテーション情報

【論文】曽宮先生と徳政女子薬科大学（韓国）のJung博士、ASAN医学研究所（韓国）のJeong博士, Choi博士との共同研究成果がNanomedicineに採択されました。 　(更新 2017.11.17)

Low immunogenic bio-nanocapsule based on hepatitis B virus escape mutants

Joohee Jung, PhD a, b, †, Masaharu Somiya, PhD a, †, Seong-Yun Jeong, PhD c, Eun
Kyung Choi, MD, PhD c,d, and Shun’ichi Kuroda, PhD a, *

Bio-nanocapsules (BNCs) consisting of hepatitis B virus surface antigen (HBsAg) L
proteins and phospholipids are used as efficient non-viral carriers for liver-specific
delivery of genes and drugs. Considering the administration to HB vaccinees and HB
patients, endogenous anti-HBsAg immunoglobulins (HBIGs) may reduce the delivery
efficacy and prevent repetitive administration. Therefore, low immunogenic BNCs were
generated by inserting two point mutations in the HBsAg L protein, which were found
in HBV escape mutants. Escape mutant-type BNC (emBNC) showed 50% lower HBIG
binding capacity than that of parental BNC (wtBNC). It induced HBIG production to a
lesser extent than that associated with wtBNC in BALB/c mice. The emBNC could
accumulate into human hepatocyte-derived tumor in mice pre-treated with HBIGs. The
complex of emBNC and cationic liposomes could deliver plasmid DNA to HepG2 cells
efficiently in the presence of HBIGs. Thus, emBNC could evade HBIG-neutralizing
antibodies, expanding the clinical utility of BNC-based nanomedicine.